Advertisement

Infections by pandrug-resistant gram-negative bacteria: clinical profile, therapeutic management, and outcome in a series of 21 patients

  • C. Tsioutis
  • E. I. Kritsotakis
  • S. Maraki
  • A. GikasEmail author
Article

Abstract

Clinical reports on infections by pandrug-resistant (PDR) bacteria are scarce. This observational case series study was conducted during a 2-year period at a university hospital. Patients infected by PDR gram-negative bacteria comprised the study cohort. An isolate was defined as PDR if it was resistant to all antibiotic classes available for empirical treatment. A total of 21 patients infected by PDR gram-negative bacteria were recorded. The mean APACHE II score on admission was 18.8, the mean Charlson comorbidity index was 2.9, and 20 (95.2%) patients had a history of intensive care unit hospitalization. All patients had recent exposure to multiple antibiotics (median, 6 antibiotic groups). Infections occurred at a mean of 41.5 days after admission. The mean length of stay after infection was 54.6 days and 5 (23.8%) patients died due to the infection. Treatment was mainly based on a colistin-containing regimen (47.6%) or tigecycline (33.3%). All patients treated with tigecycline had total resolution of the infection and a notably shorter length of hospital stay after infection. In conclusion, PDR gram-negative bacterial infections are associated with considerable prolongation of hospitalization and mortality, although the mortality is not as high as that expected. Tigecycline appears to be effective for the successful treatment of PDR infections.

Keywords

Linezolid Meropenem Moxifloxacin Colistin Charlson Comorbidity Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

None.

Financial support

None.

References

  1. 1.
    Beno P, Krcmery V, Demitrovicova A (2006) Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin Microbiol Infect 12:497–498. doi: 10.1111/j.1469-0691.2006.01364.x CrossRefPubMedGoogle Scholar
  2. 2.
    Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A (2005) Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 5:24–30. doi: 10.1186/1471-2334-5-24 CrossRefPubMedGoogle Scholar
  3. 3.
    Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A (2008) Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 32(5):450–454. doi: 10.1016/j.ijantimicag.2008.05.016 CrossRefPubMedGoogle Scholar
  4. 4.
    Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A, Nanas S, Paniara O, Roussos C, Giamarellos-Bourboulis E, Routsi C, Zakynthinos SG (2007) Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med 33:1524–1532. doi: 10.1007/s00134-007-0683-2 CrossRefPubMedGoogle Scholar
  5. 5.
    Elemam A, Rahimian J, Mandell W (2009) Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 49(2):271–274. doi: 10.1086/600042 CrossRefPubMedGoogle Scholar
  6. 6.
    Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818–829CrossRefPubMedGoogle Scholar
  7. 7.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMedGoogle Scholar
  8. 8.
    Falagas ME, Bliziotis IA (2007) Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 29:630–636. doi: 10.1016/j.ijantimicag.2006.12.012 CrossRefPubMedGoogle Scholar
  9. 9.
    Horan TC, Gaynes RP (2004) CDC definitions for nosocomial infections. In: Mayhall CG (ed) Hospital epidemiology and infection control, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 1659–1702Google Scholar
  10. 10.
    Clinical and Laboratory Standards Institute (2007) Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, WayneGoogle Scholar
  11. 11.
    European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee (2006) EUCAST technical note on tigecycline. Clin Microbiol Infect 12:1147–1149. doi: 10.1111/j.1469-0691.2006.01578.x CrossRefGoogle Scholar
  12. 12.
    Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME (2008) Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62:895–904. doi: 10.1093/jac/dkn311 CrossRefPubMedGoogle Scholar
  13. 13.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group (2008) A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 62(Suppl 1):i29–i40. doi: 10.1093/jac/dkn249 CrossRefPubMedGoogle Scholar
  14. 14.
    Navon-Venezia S, Leavitt A, Carmeli Y (2007) High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59:772–774. doi: 10.1093/jac/dkm018 CrossRefPubMedGoogle Scholar
  15. 15.
    Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, Husain S, Kwak EJ, Bhat SV, Paterson DL (2007) Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59:128–131. doi: 10.1093/jac/dkl441 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • C. Tsioutis
    • 1
  • E. I. Kritsotakis
    • 2
  • S. Maraki
    • 3
  • A. Gikas
    • 1
    • 2
    • 4
    Email author
  1. 1.Infection Control UnitUniversity Hospital of HeraklionCreteGreece
  2. 2.Laboratory of Infectious DiseasesUniversity of CreteCreteGreece
  3. 3.Laboratory of Clinical Bacteriology, Parasitology, Zoonoses, and Geographical MedicineUniversity of CreteCreteGreece
  4. 4.Department of Infectious DiseasesUniversity Hospital of HeraklionHeraklion, CreteGreece

Personalised recommendations